AUC 5 IV (max
Carboplatin IV 605 mg H2
800mg)
Etoposide 100 mg/m2 IV 180 mg H 1-3
Literatur:
1. Divisi HOM Bandung. (2016). Buku Saku Kemoterapi & Gawat Darurat
Onkologi: Regimen NHL. Bandung
2. Kewalramani, T., Zelenetz, A. D., Nimer, S. D., Portlock, C., Straus, D., Noy,
A.,Moskowitz, C. H. (2004). Rituximab and ICE as second-line therapy before
autologous stem cell transplantation for relapsed or primary refractory diffuse
large B-cell lymphoma. Blood, 103(10), 3684–3688.
3. Hertzberg, M. S., Crombie, C., Benson, W., Taper, J., Gottlieb, D., & Bradstock,
K. F. (2006). Outpatient fractionated ifosfamide, carboplatin and etoposide as
salvage therapy in relapsed and refractory non-Hodgkin’s and Hodgkin’s
lymphoma. Annals of Oncology, 17 Suppl 4(suppl_4), iv25-30.